# Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC)

> **NCT04410887** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Stomach Cancer
- Gastric Cancer

## Interventions

- **DRUG:** PIPAC+SOX+OLAPARIB

## Key facts

- **NCT ID:** NCT04410887
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12
- **Primary completion:** 2021-12
- **Final completion:** 2022-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04410887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04410887, "Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04410887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*